Enhancing the Efficacy of Immune Checkpoint Inhibitor Therapy Using a Novel Treatment Combination
PHILADELPHIA — (Sept. 5, 2018) — A combination of a novel inhibitor of the protein CK2 (Casein kinase 2) and an immune checkpoint inhibitor has dramatically greater antitumor activity than either inhibitor alone, according to research from The Wistar Institute that was published online in Cancer Research.
Immune checkpoint inhibitors have been approved to treat several types of cancer, including some types of lung cancer and colon cancer, but not all patients who receive these immunotherapeutics gain benefit from them. A better understanding of the molecular reasons why some patients do not respond to immune checkpoint inhibitors could identify new therapeutic targets for combination treatments that may improve clinical outcomes.
“A population of immune cells called myeloid-derived suppressor cells (MDSC) has been implicated in tumor resistance to various types of cancer treatment, including immune checkpoint inhibitors,” said lead researcher Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and program leader of the Immunology, Microenvironment & Metastasis Program at Wistar. “We have previously shown that accumulation of the most abundant type of MDSC, polymorphonuclear MDSC (PMN-MDSC), is caused by downregulation of Notch signaling, in part as a result of CK2 activity.”
Based on these previous results, Gabrilovich and collaborators set out to investigate whether combining inhibitors of CK2 with immune checkpoint inhibitors could improve immune responses in mouse models of cancer and to determine what mechanisms of action caused the results they obtained.
“Our new data suggest that using a CK2 inhibitor to manipulate the tumor microenvironment may sensitize patients to the effect of an immune checkpoint inhibitor and thereby improve clinical outcomes, although this needs to be tested in clinical trials,” said Ayumi Hashimoto, a postdoctoral fellow in the Gabrilovich Lab and first author on the paper.
The researchers found that a combination of the CK2 inhibitor BMS-595 and the immune checkpoint inhibitor anti-CTLA-4-mIgG2a had antitumor activity in three different mouse models of cancer: a lung cancer, a colon cancer, and a lymphoma model. More than 60 percent of mice who received the combination treatment completely eliminated the tumor while none of the mice that received either single agent alone completely eliminated the tumor.
The mechanism of the effect of BMS-595 was analyzed, and in-depth studies showed that two of the main types of immune cells affected by the CK2 inhibitor in tumor-bearing mice were PMN-MDSCs and another type of myeloid cell called tumor-associated macrophages (TAMs). The frequency of PMN-MDSCs was not significantly altered in tumors, but it was substantially decreased in the spleen, an organ that is a part of the immune system. TAMs were decreased in the tumor.
“Our study shows that CK2 inhibition blocks the differentiation of PMN-MDSCs and TAMs, meaning that it blocked the generation of these cells from their precursors. This led to a decrease in immunosuppressive PMN-MDSCs and tumor-promoting TAMs and thus to a substantial augmentation of the antitumor activity of immune checkpoint blockade,” added Gabrilovich.
The research was supported by National Institutes of Health grant RO1 CA084488 and a grant from Bristol-Myers Squibb. Core support for The Wistar Institute was provided by the Cancer Center Support Grant P30CA010815.
Wistar co-authors include Ayumi Hashimoto, Jerome Mastio, and Andrew Kossenkov. Other co-authors include Scott I. Abrams from Roswell Park Comprehensive Cancer Center; and Chan Gao, Ashok V. Purandare, Heshani Desilva, Susan Wee, John Hunt, and Maria Jure-Kunkel from Bristol-Myers Squibb.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.
Print this Page
For press inquiries or more information please contact firstname.lastname@example.org